The nation of Zimbabwe has turned down a substantial US health deal valued at $367m (£272m) over five years because of the United States' demand for confidential information.
This move was revealed after a official document from December was disclosed, revealing that President Emmerson Mnangagwa felt the deal was "lopsided".
A government representative later explained that the US was requesting genetic material for research and commercial purposes but refused to guarantee the resulting advantages from any future treatments.
"We must now begin the difficult and regrettable process of scaling back our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for more dialogue to find a deal suitable to all parties so the nation's critical HIV programme can continue.
Wider Context
This rejection follows a comparable situation in neighbouring Kenya, where a high court blocked a similar deal with the US after legal challenges were raised about the safety of Kenyans' medical information.
Since resuming office recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
USAID had managed aid for the American government, but Trump claimed its spending was "wasteful" and his government was seeking government-to-government agreements to boost openness and accountability.
As per reports, 16 nations in Africa have so far signed these new agreements, representing over $18.3bn of fresh investment.
Details of the Declined Agreement
The funds for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation could have provided significant benefits for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment through American-funded programmes," the Ambassador said.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Our nation was requested to provide its biological resources and data over an extended period, without any equivalent assurance of benefiting from any scientific breakthroughs – like new medicines or tests – that might be developed from that shared data," he stated.
"In essence, our country would provide the raw materials for medical research with no assurance that the final treatments would be accessible to our population should a future health crisis arise."
National Interest and Global Health
Mangwana further noted that the American exit from the global health body and its pursuit of one-on-one deals were disrupting structures already established through the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing system designed to deal with potential pandemics.
"This mechanism is intended to ensure that when a nation provides its samples, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the funds to develop them."
These objections over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We are open to further dialogue with our American counterparts on how subsequent co-operation might be structured in a way that honours the sovereignty and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the official position, but urged that talks need to persist given that a large portion of the country's HIV programmes were funded by international support.
"In cases where technical issues exist, including those involving information security or agreement terms, these can often be addressed via technical clarification and negotiated safeguards," it added.
This impasse highlights the complex debate between accepting vital international aid and safeguarding national sovereignty in an ever more data-driven world.